1. Home
  2. UVV vs IMTX Comparison

UVV vs IMTX Comparison

Compare UVV & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Corporation

UVV

Universal Corporation

SELL

Current Price

$37.73

Market Cap

1.1B

Sector

Industrials

ML Signal

SELL

Logo Immatics N.V.

IMTX

Immatics N.V.

SELL

Current Price

$6.21

Market Cap

992.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
UVV
IMTX
Founded
1886
N/A
Country
United States
Germany
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
992.8M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
UVV
IMTX
Price
$37.73
$6.21
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $15.97
AVG Volume (30 Days)
379.7K
★ 1.0M
Earning Date
11-04-2026
11-10-2026
Dividend Yield
★ 8.83%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.30
N/A
Revenue
★ $2,885,078,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.17
$14.22
P/E Ratio
$125.27
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$37.38
$6.07
52 Week High
$59.38
$12.41

Technical Indicators

Market Signals
Indicator
UVV
IMTX
Relative Strength Index (RSI) 35.46 33.37
Support Level N/A N/A
Resistance Level $54.25 $7.95
Average True Range (ATR) 1.29 0.46
MACD -0.10 -0.02
Stochastic Oscillator 6.14 8.26

Price Performance

Historical Comparison
UVV
IMTX

About UVV Universal Corporation

Universal Corp is an international leaf tobacco supplier. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Tobacco Operations segment involves procuring and processing flue-cured, burley, dark air-cured, and oriental leaf tobacco for manufacturers of consumer tobacco products and performing related services. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, the Philippines, Germany, and Other Countries, with the majority of revenue from the USA.

About IMTX Immatics N.V.

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Share on Social Networks: